Abhinav Sidana, MD is a Urologic Surgeon specializing in the diagnosis and management of urologic cancers. Dr. Sidana completed medical schooling at All India Institute of Medical Sciences, New Delhi. After graduation, he joined the Brady Urological Institute of Johns Hopkins Hospital as a postdoctoral fellow where he worked on translational projects relating to cancer immunotherapy and was instrumental in translating the preclinical work to a clinical trial on ‘cryoimmunotherapy’. He then completed Urology residency at the University of Cincinnati Medical Center. Subsequently, he completed a Urologic Oncology fellowship at the National Cancer Institute, National Institutes of Health. Dr. Sidana’s clinical practice includes both surgical and non-operative management of prostate, kidney, ureteral, testicular, and bladder cancers. Dr. Sidana’s research interests include functional prostate imaging, image-guided and focal treatments for prostate cancer and clinical trials on novel treatments for urologic cancers.

Education:

• Bachelor of Medicine & Bachelor of Surgery (MBBS): All India Institute of Medical Sciences, 2007
• Post Doctoral Fellowship in Urology: Johns Hopkins University School of Medicine, 2010
• Urology Residency: University of Cincinnati College of Medicine, 2015
• Urologic Oncology Fellowship: National Cancer Institute, National Institutes of Health, 2017

Cridentials:

• 4/2015- 6/2017 Maryland State Medical License
• 5/2016- Present District of Columbia Medical License
• 5/2017- Present Ohio State Medical License
• Board Eligible: American Board of Urology

Professional Affiliations:

• Member, American Urological Association (AUA)
• Member, The Endourological Society
• Member, The Society of Urologic Oncology
• Member, American Medical Association

Publications:

• Jain AL and Sidana A (2016). Therapeutic Strategies for Hereditary Kidney Cancer: Beyond the Abstract. OncToday.com. .
• Sidana A, Watson M and Pinto PA (2016). MRI-TRUS Fusion Prostate Biopsy Outperforms 12-core Systematic Prostate Biopsy in Patients with Prior Negative Systematic Biopsy. AUA News. .
• Sidana A (2011). Beyond the Abstract - Does valproic acid induce neuroendocrine differentiation in prostate cancer?. UroToday.com. .
• Sidana A (2008). The M&M Matrix: What Does It Mean to a Medical Student?. General Surgery News, Sep:35:9. .
• Jain AL and Sidana ADeterminants and prognostic implications of malignant ascites in metastatic papillary renal cancer: Beyond the Abstract. OncToday.com. .

Awards:

• 2000: National Talent Search Examination (NTSE) Scholarship. Awarded by National Council of Educational Research and Training, Government of India
• 2000: All India Jagriti Independence Scholarship. Awarded by National Centre for Talent Promotion, Rashtriya Jagriti Sansthan, Government of India
• 2004: Kishore Vaigyanik Protsahan Yojna (KVPY) Research Scholarship, Government of India
• 2007: Foreign Travel Grant, Council of Scientific & Industrial Research Human Resource Development Group, Government of India
• 2009: Best Poster Award, Johns Hopkins Post-Doctoral Association Annual Poster Session, Baltimore, MD
• 2012: Urology Scholar Award, University of Cincinnati College of Medicine, Cincinnati, OH
• 2013: Art Evans Award for excellence in urological research, University of Cincinnati College of Medicine, Cincinnati, OH
• 2014: Best Clinical Abstract, Ohio Urological Society (OUS) Annual Meeting, Cincinnati, OH
• 2014: Urology Scholar Award, University of Cincinnati College of Medicine, Cincinnati, OH
• 2014: Art Evans Award for excellence in urological research, University of Cincinnati College of Medicine, Cincinnati, OH
• 2014: Alpha Omega Alpha Honor Medical Society, University of Cincinnati College of Medicine, Cincinnati, OH
• 2015: Art Evans Award for excellence in urological research, University of Cincinnati College of Medicine, Cincinnati, OH
• 2015: Quality Improvement and Safety Award, University of Cincinnati College of Medicine, Cincinnati, OH
• 2016: Best Moderated Poster, Prostate Cancer: Detection & Screening, American Urological Association (AUA) Annual Meeting, San Diego, CA
• 2016: Best Moderated Poster, Kidney Cancer: Epidemiology & Evaluation/Staging, American Urological Association (AUA) Annual Meeting, San Diego, CA

Contact Information

UC Health Physicians Office (Clifton)

222 Piedmont Avenue
Cincinnati, Ohio 45219
Phone: (513) 475-8787

  Shuchi Gulati, MD FACP is a Medical Oncologist who specializes in the diagnosis and management of
urologic cancers. She completed her medical school in India and after completing her Internal Medicine
Residency in Pennsylvania moved to Cincinnati. She completed a Hematology and Oncology fellowship
at University of Cincinnati in 2018 and is currently pursuing a Masters in Clinical Translational Research.
Her clinical practice is located at Barrett Cancer Centre, University of Cincinnati; where she provides care
to patients with prostate, kidney, bladder, urethral and testicular cancer. She is also a part of the phase
1/ early phase clinical trials team. Her research interest is in immunotherapy drug mechanisms and
hopes to make immunotherapy based clinical trials available to patients at University of Cincinnati as
well as in the community. Outside of work, Dr. Gulati loves to explore the outdoors and the various
parks in Cincinnati with her husband and three children. They enjoy baseball and proudly support the
Reds!

Education:
2008: Bachelor of Medicine and Bachelor of Science (MBBS): Dr. Rajendra Prasad Medical College, India
2010: Internship Cleveland Clinic Health System at Fairview Hospital
2012: Residency (Internal Medicine), the Reading Hospital and Medical Center, PA
2018: Fellowship (Hematology/ Oncology), University of Cincinnati
2019- ongoing: Masters in Clinical and Translational Research, University of Cincinnati

Credentials Board Certifications:
2008: Education Commission for Foreign Medical Graduates (ECFMG), certified
2012: American Board of Internal Medicine; certified
2018: American Board of Internal Medicine- Hematology; certified
2018: American Board of Internal Medicine- Oncology; certified
2012- current: State Medical Board of Ohio license
2010- 2012: PA State Board Medical license

Professional Organization Memberships: 
Fellow, American College of Physicians (FACP)
Associate Member, American Society of Clinical Oncology (ASCO)
Associate Member, American Society of Hematology (ASH)
Member, Society for Immunotherapy of Cancer (SITC)
Member, South-West Oncology Group (SWOG) Genitourinary Cancer Committee
Member, Hoosier Cancer Research Network (HCRN) Genitourinary Clinical Trial Working Group

Publications:
Gulati S, Wise- Draper, et al. Interim analysis of the combination of durvalumab and cetuximab in a
phase II trial of patients with recurrent and metastatic head and neck squamous cell carcinoma. SITC
annual meeting 2019
Gulati S, Elsisi Z, et al. Low Molecular Weight Heparin Vs Direct Oral Anticoagulants (Apixaban, Edoxaban
and Rivaroxaban) for the Treatment of Cancer Associated Thrombosis: A Cost- Effective Analysis. SMDM
annual meeting 2019
Gulati S, Desai J, Wise-Draper TM. Phase-I dose-finding study of metformin in combination with
concurrent cisplatin and radiation in patients with locally advanced head and neck squamous cell cancer.
Cancer
Gulati S, Wise-Draper TM et al. Preliminary effects on the innate immune system with the combination
of Cetuximab and Durvalumab in Metastatic/ Relapsed Head and Neck Squamous Cell Carcinoma in a
Phase II trial. JCO 37, e14273–e14273 (2019)
Gulati S, Yaniv B, Wise-Draper TM et al. A phase I dose-finding study of metformin in combination with
concurrent cisplatin and radiation in patients with locally advanced head and neck squamous cell
carcinoma. JCO. 2018;36(15_suppl): 6074-6074
Hassan R, Gulati S et al. Impact of Low Molecular Weight Heparin on Overall Survival in Patients with
Advanced Lung Cancer: A Retrospective Study. American Journal of Clinical and Experimental Medicine.
2017;5(5):173-175
Gulati S, Takiar V, Wise-Draper TM et al. Impact of metformin on survival and mTOR pathway in head
and neck cancer patients: An updated analysis. JCO. 2017;35(15_suppl):e17500-e17500
Gulati, S., Xie, C., Butler, R., Wise-Draper, T. Impact of metformin on survival and mTOR pathway in head
and neck cancer. JCO 34, e17514–e17514 (2016)
Agarwal R, Gulati S, Olowokure OO et al. Advanced biliary tract cancer: clinical outcomes with ABC-02
regimen and analysis of prognostic factors in a tertiary care center in the United States. J Gastrointest
Oncol. 2016;7(6):996-1003
Yellu, M., Gulati, S., et al. Survival Impact of Concomitant Medications in Advanced Lung Cancer. Journal
of thoracic oncology (Vol. 10, No. 9, pp. S765-S765)
Karim, NA., Gulati, S., et al. Impact of Endobronchial Stents on Patients with NSCLC and Central Airway
Obstruction (CAO). Journal of thoracic oncology (Vol. 10, No. 9, pp. S652-S653)
Gulati S, Abdel Karim NF et al. Impact of low molecular weight heparin on overall survival in patients
with advanced lung cancer: A retrospective study. JCO. 2015;33(15_suppl):e19150-e19150
Siddiqi NI, Abdel Karim NF et al. Impact of tricyclic antidepressants (TCAs), SSRIs, and other
antidepressants on overall survival in patients with advanced lung cancer. JCO.
2015;33(15_suppl):e22237-e22237
Gulati S, Corrêa ZM, Medlin S et al. Ocular Adnexal Lymphoma Presenting with Visual Loss. N Am J Med
Sci. 2016;8(1):56-60

Gulati S, Donato AA. Lupus anticoagulant and ANCA associated thrombotic vasculopathy due to cocaine
contaminated with levamisole: a case report and review of the literature. J Thromb Thrombolysis.
2012;34(1):7-10
Gulati S, Daw H and Gustafson S. PMS2 Mutation and Lynch Syndrome: Understanding Current
Concepts. Gastrointestinal Cancer Res.2011 Sep; 4(5-6): 188-90

Contact Information

UC Health Barrett Cancer Center

234 Goodman Street
Cincinnati, Ohio 45219
Phone: (513) 475-8500
Fax: (513) 584-8554

Link to Sidana's Power Point Presentation